Parathyroid Hormone Secretory Responses to Peroral Phosphate and Stimulability of Serum Levels of Carboxyl-Terminal Flanking Peptide (PND-21) of the Human Calcitonin Gene by Calcium in Normal Subjects and Osteoporotic Patients
The roles of calciotropic hormones in the pathogenesis and treatment of osteoporosis are not clearly understood. Here we have assessed serum levels of immunoreactive parathyroid hormone (PTH) and urinary cyclic AMP excretion before and after acute peroral phosphate administration in osteoporotic patients and normal subjects of the same age. In some osteoporotic patients serum levels of PTH were measured after prolonged (5 days) treatment with peroral phosphate. Serum levels of immunoreactive carboxyl-terminal flanking peptide (PDN-21) (katacalcin is a synonym) of the human calcitonin gene which are closely related to calcitonin levels were also measured before and after iv calcium injections (1). The diagnosis of osteoporosis was established on the basis of at least one vertebral compression fracture. Control subjects had normal serum levels of calcium, phosphate and creatinine, and they presented no history of renal, hepatic and intestinal disease. None of the subjects were treated with glucocorticoids or were alcoholics.
KeywordsParathyroid Hormone Osteoporotic Patient Human Parathyroid Hormone Human Calcitonin Calciotropic Hormone
Unable to display preview. Download preview PDF.
- 1.J. Ittner, M. A. Dambacher, W. Born, J.-M. Ketelslegers, M. Buysschaert, P. M. Albert, A. E. Lambert, and J. A. Fischer, Diagnostic evaluation of measurements of carboxyl-terminal flanking peptide (PDN-21) of the human calcitonin gene in human serum, J. Clin. Endocrinol. Metab. 61: in press (1985).Google Scholar
- 2.C. Nagant de Deuxchaisnes, J. A. Fischer, M. A. Dambacher, J.-P. Devogelaer, C. E. Arber, J. M. Zanelli, J. A. Parsons, N. Loveridge, L. Bitensky, and J. Chayen, Dissociation of parathyroid hormone bio-activity and immunoreactivity in pseudohypoparathyroidism type I, J. Clin. Endocrinol.Metab. 53: 1105 (1981).CrossRefGoogle Scholar
- 7.J. C. Gallagher, B. L. Riggs, C. M. Jerpbak, and C. D. Arnaud, The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women, J. Lab. Clin. Med. 95: 373 (1980).Google Scholar
- 8.J. Reeve, P. J. Meunier, J. A. Parsons, M. Bernat, 0. L. M. Bijvoet, P. Coupron, C. Edouard, L. Klenerman, R. M. Neer, J. C. Renier, D. Slovik, F. J. F. E. Vismans, and J. T. Potts Jr., Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial, Brit. Med. J. ii: 1340 (1980).Google Scholar
- 10.H. Rasmussen, P. Bordier, L. Auquier, J. B. Eisinger, D. Kuntz, F. Caulin, B. Argemi, J. Gueris, and A. Julien, Effect of combined therapy with phosphate and calcitonin one bone volume in osteoporosis, Bone 2: 107 (1980).Google Scholar
- 14.C. J. Hillyard, G. Abeyasekera, R. K. Craig, C. Myers, J. C. Stevenson, and I. Maclntyre, Katacalcin: A new plasma calcium-lowering hormone, Lancet i: 846 (1983).Google Scholar
- 16.C. J. Hillyard, J. C. Stevenson, and I. Maclntyre, Relative deficiency of plasma-calcitonin in normal women, Lancet i: 961 (1978).Google Scholar
- 19.H. M. Taggart, J. L. Ivey, K. Sisom, C. H. Chesnut III, D. J. Baylink, M. B. Huber, and B. A. Roos, Deficient calcitonin response to calcium stimulation in postmenopausal osteoporosis?, Lancet i: 475 (1982).Google Scholar
- 21.R. Lindsay, D. M. Hart, J. M. Aitken, E. B. MacDonald, J. B. Anderson, and A. C. Clarke, Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment, Lancet i: 1038 (1976).Google Scholar
- 23.R. P. Heaney, J. C. Gallagher, C. C. Johnston, R. Neer, A. M. Parfitt, and G. D. Whedon, Calcium nutrition and bone health in the elderly, Am. J. Clin. Nutr. 36: 986 (1982).Google Scholar
- 24.J. F. Aloia, S. H. Cohn, J. A. Ostuni, R. Cane, and K. Ellis, Prevention of involutional bone loss by exercise, Ann. Intern. Med. 89: 356 (1978).Google Scholar